evoke trial semaglutide and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of in early-stage symptomatic Alzheimer's disease | Alzheimer's Research & Therapy Semaglutide showed limited improvements in

Contributing to the occlusion of sick arteries can worsen the condition, potentially leading to thrombosis (170)

Despite promising development in metabolic therapy, regulatory complexity, funding gaps and strategic constraints prevented its international launch

In the United States, the FDA warns that there are no injectable products approved to lighten skin - none

Applied Clinical Trials Online, 2026

This study found no evidence reasonably suggesting an association between GLP-1RA and SSIBs based on clinical characteristics, TTO, disproportionality, and co-medication analysis

PalaLPezzatiniADicembriniICianiSGelminiSVannelliBGet al